Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her PhD dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis Systemic Lupus Erythematosis. As founder and president of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery.

she is interested in developing methods to increase the speed of biomarker discovery.

Tao Chen has completed his Ph.D. from University of Arkansas for Medical Sciences, diplomat of the American Board of Toxicology and postdoctoral studies from Duke University. He has been a Principal Investigator in National Center for Toxicological Research since 2010 and is also an Adjunct Professor in two universities. He has served as an editorial board member and reviewer in a number of journals, a consultant for the World Health Organization, a reviewer for research proposals for US National Science Foundation. He has published more than 200 manuscripts and abstracts in peer-reviewed journals and books, and scientific meetings.

He has been a Principal Investigator in National Center for Toxicological Research

Lori A. Henderson is a Program Director at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), an institute at the National Institutes of Health (NIH), and has 17 years experience with technical and managerial expertise in several scientific areas: bioengineering, biotechnology, materials science, nanotechnology, enzymology, and biomedical technologies. She currently manages the Nanotechnology and Drug and Gene Delivery programs within the Division of Discovery Science and Technology in the Extramural Division of the NIBIB. She also represents the NIH on the National Science and Technology Council (NSTC) subcommittee on Nanoscale Science, Engineering & Technology (NSET). Her responsibilities at the NIH also include co-managing projects within the Nanomedicine, Interdisciplinary Research, and Regulatory Science programs supported by the NIH Common Fund. These trans-NIH and trans-agency programs include research projects that cut across scientific disciplines and challenges conventional thinking. Prior to the NIH, Dr. Henderson was a Group Leader of the Biomaterials Group within the Polymers Division at the National Institute of Standards and Technology (NIST). Before joining NIST in 2005, Dr. Henderson worked for Novozymes North America, BASF, and Akzo Nobel, where she was a research supervisor, global project leader, and a senior scientist. Dr. Henderson holds a M.S. degree in Macromolecular and Organic Chemistry, and obtained a Ph.D. in Polymer Science from University of Massachusetts, Lowell.

Clinical Trials Branch/Cancer Imaging Program

Alan Prem Kumar earned his Ph.D. from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas. Dr. Kumar then pursued Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors. Dr. Kumar relocated back to Singapore to join Cancer Science Institute of Singapore, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer pharmacology. His current research interest includes the role of nuclear receptors involved in the regulation of target genes and to elucidate mechanism and associated signal pathways. Another area of interest is aimed at developing new derivative drugs with hopefully fewer side effects. Over the years, Dr. Kumar and his laboratory have forged relationships with scientists in cancer research and with cancer advocacy groups in Singapore.

My primary research focuses in the areas of signaling by nuclear receptors and oncogenes as well as the development of molecular therapeutics and biomarkers of drug action in human breast cancer. We recently identified a novel oncogene that regulates a key pathway controlling cell proliferation, migration and drug resistance in breast, prostate, gastric, and colon cancers. Current research also focuses on developing therapeutic strategies to target this marker with the ultimate aim of conducting translational studies in patients.

Research and Working experience: March 2011-date as Assistant Research Professor, Biosample Repository Facility, Fox Chase Cancer Center, Philadelphia. Jan 2006-Dec 2010 as Instructor, Department of Pathology and Laboratory Medicine, UMDNJ-Robert Wood Johnson Medical School, New Jersey. March 2002 - Jan 2006 as Research Associate, Fox Chase Cancer Center, Philadelphia. Aug 2000 - Feb 2002 as Postdoc Associate, Fox Chase Cancer Center, Philadelphia. Apr 1997 - July 2000 Faculty member (instructor), Department of Anatomy and Cell Biology, Kagoshima University Faculty of Medicine, Japan. Aug 1990 - Jan 1993 Microbiology Inspector, Import and Export Commodities Inspection Bureau, GuangZhou, China.

Immunohistochemistry (IHC) for both basic and clinical research, Gene regulation on embryogenesis, organogenesis, tumorigenesis and multi-drug resistance, automatic quantitative analysis (AQUA) on both basic and clinical research, particularly in biomarker characterization and discovery, Ovarian cancer biology, understanding the molecular alterations of known and novel signaling pathways that regulate embryogenesis, organ morphogenesis, preneoplastic transformation and tumorigenicity

Neil Box is a Assistant Professor in the Department of Dermatology at the University of Colorado Denver. He is a member of the University of Colorado Cancer Center, Skin Diseases Research Center and the Charles C. Gates Regenerative Medicine and Stem Cell Biology Center. He is an active member of the Skin Cancer Tissue Bank executive committee. He has received Research Career Development Awards from the Dermatology Foundation and the American Skin Association. Dr. Box completed his graduate school training on the genetics of human hair, skin and eye color in the laboratory of Dr. Richard Sturm at the University of Queensland, Australia. During this period he identified some of the key red hair color variants at the MC1R locus (eg. R151C, R160W). His subsequent research on this subject produced some of the seminal melanoma association and gene interaction studies for MC1R. Since moving to the USA in 2001, he performed postdoctoral trained with two leading scientists in mouse models of human disease: Dr. Monica Justice and Dr. Dennis Roop at Baylor College of Medicine. From this work, he has assembled a research program aimed at uncovering the molecular mechanisms regulating melanoma risk. Since his recruitment to the University of Colorado in 2007, he has also continued his interests in working with human melanoma risk genes to explore their potential clinical and public health applications.

The mouse as a model for human melanocyte and melanoma development.

Yuxun Wang is currently the Executive Director and Head of Cancer Biology at HD Biosciences. He has a blend of experiences in both academia and biopharmaceutical industry in the US. Previously, he was associate director at Metamark Genetics, assistant professor at University of South Carolina and senior scientist at Merck Research Laboratory. His research has focused on translational oncology, cancer drug and predictive biomarker discovery. He has over 24 research publications and patent, numerous conference presentations and invited talks. He has received a number of awards recognizing his research and service in both academia and industry.

Head of Cancer Biology at HD Biosciences. He has a blend of experiences in both academia and biopharmaceutical industry in the US

Geetika Chakravarty's research is geared towards the identification and evaluation of new cancer stem cell biomarkers and novel strategies to target them using breast cancer as the model system. Her research has resulted in patents, invited book chapter and several first and co-authored publications. She is also dedicated to help maintain the most rigorous standards of scientific inquiry and progress and as such serves as the editorial board member and journal reviewer of cancer related journals.

Her research is geared towards the identification and evaluation of new cancer stem cell biomarkers and novel strategies to target them using breast cancer as the model system. Her research has resulted in patents,

Sevtap Savas obtained her Ph.D. in Molecular Biology and Genetics in 1999. She was trained as a post-doctoral trainee and a Research Associate at Louisiana State University (USA), Mount Sinai Hospital Research Institute (Canada) and Princess Margaret Hospital/Ontario Cancer Institute (Canada), before joining the Memorial University (Canada) as an Assistant Professor in 2008. She has a multidisciplinary research program integrating molecular genetics, bioinformatics, biostatistics and epidemiology and currently focuses on identification of genetic markers that can predict clinical outcome in colorectal cancer patients.

Role of genetic variation in cancer susceptibility; Role of genetic variation in treatment response (pharmacogenetic), Role of genetic variation in clinical outcomes and survivorship in cancer; Role of somatic mutations in cancer predisposition treatment response and clinical outcome; Role of mitochondrial genome in cancer predisposition, treatment response and clinical outcome; Bioinformatics application and establishment of biological databases, High-throughput genotyping technologies and resequencing studies

Yaguang Xi got the Ph.D from Peking University after his clinical training. He is an Assistant Professor at the University of South Alabama Mitchell Cancer Institute. To date, Dr. Xi has authored 43 publications in many prestigious journals and is serving as the member of editorial board and ad-hoc reviewer for many journals and grant agencies.

Discovery and validation of novel biomarkers associated with tumor progression, metastasis, therapeutic response and chemoprevention,

Michael Holinstat is an assistant professor of Medicine at Thomas Jefferson University in Philadelphia. He received his Ph.D. in Pharmacology from the University of Illinois at Chicago and postdoctoral training at Vanderbilt University in the Department of Pharmacology. His research focuses on identifying novel approaches to anti-platelet therapy with a special emphasis on regulation of platelets through the lipoxygenase pathway leading to a number of oxidized fatty acids which may play a central role in regulating unwanted platelet activation. Additionally, the lab studies regulation of platelet signaling through PAR1 and PAR4.

Thrombosis; Rap1; Gpcr; Signal Transduction; Platelet; Pharmacology; Hematology; Medicine; Small G Protein; Signal Transduction; Signaling; Lipoxygenase; 12-Lipoxygenase; 12-HETE; 12-HETrE.

Feng Yan, has completed her Ph.D from Yangzhou University in China. She is the Vice Director of Department of Clinical Laboratory in Jiangsu Cancer Hospital, and an Professor of Nanjing Medical University. The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells. She was the Outstanding Medical Talents (2007), Excellent Medical Talent (2011) and Leading Medical Talent (2011) of Jiangsu Province. She has published more than 42 papers in reputed journals.

The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells.

Jamal Zweit is a Professor of Radiology, Radiation Oncology, Molecular Pathology, and Biochemistry & Molecular Biology. He is also the Director of the Center for Molecular Imaging at Virginia Commonwealth University Medical Center. He leads an inter-disciplinary and inter-collaborative molecular imaging research program that emphasizes multi-modality approaches to study biochemical and biological pathways in vivo. Professor Zweit's research interests include the development of paradigms for molecular imaging and nanotechnology strategies for preclinical and clinical translational research in cancer biology and therapeutics. He is internationally recognized for his work in molecular imaging of cancer drug development, and conducted the "world’s first" Molecular PET Imaging clinical trial of Anti-angiogenic therapy in cancer patients (Journal National Cancer Institute 2002). Professor Zweit serves as an advisor on a number of committees, including the Cancer Research UK Pharmacodynamic and Pharmacokiunetic Technologies Advisory Committee (Journal National Cancer Institute, 2006). He serves on the review body of a number of funding organizations, both in Europe and North America. He has supervised a total of 24 MSc, MD and PhD theses. He has published more than 100 peer reviewed articles, over 250 conference abstracts, and 6 review articles and book chapters. Professor Zweit obtained his PhD and DSc from the University of Manchester Medical School. Prior to that, He studied for an MSc degree in PET Pharmacology. He received his Nuclear Medicine training at the John F. Kennedy Medical Centre in New Jersey, and attended advanced Nuclear Medicine training at the Brooklyn Hospital in New York As an Undergraduate, he obtained his Bachelor of Science degree, in Radiation Biophysics, with a Biochemistry double major, from the University of Kansas.

Multi-modality molecular and cellular imaging. Biologically targeted probe development and ulti-probe pre-clinical imaging. Nano-particle and quantum dot molecular and cellular imaging. Translational clinical molecular imaging in drug development. Pharmacokinetics and pharmacodynamics studies in oncology and neuroscience.

Dr. Bowser is Chairman of Neurobiology and Director of the Gregory W. Fulton ALS and Neuromuscular Research Center at the Barrow Neurological Institute and St. Joseph's Hospital and Medical Center in Phoenix, AZ. He obtained his PhD from Yale University School of Medicine and was a faculty member at the University of Pittsburgh School of Medicine for 18 years prior to his arrival in Phoenix in 2011. Dr. Bowser is also co-Founder of Knopp Biosciences, LLC and Iron Horse Diagnostics, Inc., biotechnology companies advancing new treatments and ways to diagnose neurologic disorders. Iron Horse Diagnostics is commercializing the first diagnostic test for ALS. Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings to the clinic. His laboratory leads efforts in the discovery and validation of protein biomarkers for ALS. Dr. Bowser also pursues methods to monitor ALS disease progression and drug effects during clinical trials. He has national and international leadership positions in the field of ALS, and co-Chairs a national ALS Biorepository, providing biofluid and tissue samples collected using standardized procedures to ALS investigators throughout the country.

Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings to the clinic. His laboratory leads efforts in the discovery and validation of protein biomarkers for ALS. Dr. Bowser also pursues methods to monitor ALS disease progression and drug effects during clinical trials. He has national and international leadership positions in the field of ALS, and co-Chairs a national ALS Biorepository, providing biofluid and tissue samples collected using standardized procedures to ALS investigators throughout the country.

Jagat Kanwar is an Immunologist and Molecular Biochemist. He is group leader of the Laboratory of Immunology and Molecular Biomedical Research. Kanwar's research work generated in total of 12 patent/PCTs with two provisionals in preparation. Five of these patents have been licensed for commercialization to biotech companies Antisoma, NeuronZ, Neuren Pharmaceuticals and Fonterra. He was invited as a speaker in more than 30 conferences and chaired sessions in Immunology, Nanotechnology, Nanomedicine and Biotechnology.

Nanomedicine, multi-targeted oral or intravenous delivery systems, nano-medicinal based vaccines and immunotherapy, micro-fluidics and lab-on-a-chip devices.

Assistant Professor & Director MEBRL, Division of Epidemiology, 1990-Present, School of Public Health, University of Minnesota Minneapolis, MN Research Associate, Division of Epidemiology, 1987-1990, School of Public Health, University of Minnesota, Minneapolis, MN Research Fellowship, National Research Service Award, 1984-1987 Endocrine Research Unit, Mayo Clinic, Rochester, MN Dr. Gross is Director of the Molecular Epidemiology and Biomarker Research Laboratory at the University of Minnesota. He has overseen analysis for numerous epidemiologic projects and has published extensively in the areas of antioxidants and oxidative damage. His experience includes serving as principal investigator of the laboratory core for the University of Minnesota CPRU program project, co-principal investigator of YALTA and as co-investigator of several clinical trials and epidemiologic studies emphasizing diet, genetics and biological markers. His laboratory has served as an analytical facility for several multicenter studies including CARDIA, ARIC and CATCH. Sample tracking, data handling, biochemical analysis and sample storage for large epidemiologic studies are a routine part of his laboratory.

Biomarker development/translational research, molecular/biochemical epidemiology, antioxidants, oxidative damage and risk of cardiovascular disease, DNA repair and genetic susceptibility in the risk of breast cancer, early detection of pancreatic prostate cancer, dietary and genetic factors in Alzheimer’s and successful aging